DRIO

DarioHealth is a chronically loss-making micro-cap ($53M market cap) whose numbers do not support the platform growth story management tells in the MD&A. Despite pitching a 'vertically integrated health intelligence platform' with 100+ signed contracts and the Twill/Upright/PsyInnovations acquisitions, FY2025 revenue FELL 17.3% to $22.4M, and the five-year revenue line is flat-to-down and lumpy ($20.5M→$27.7M→$20.4M→$27.0M→$22.4M). The B2B2C model is not compounding. Net income was -$41.7M on a -186.6% net margin, operating margin was -163.9%, and the accumulated deficit has ballooned to -$452M — this company has never earned money and is burning through what it raises.

The headline 'P/E of 0.7' on diluted EPS of $10.12 is a data artifact, not value: a company that lost $41.7M cannot have positive EPS, and shares outstanding collapsed 82.4% YoY (to 7.30M) — a large reverse split, the classic move to cure a sub-$1 Nasdaq compliance price. Ignore the P/E entirely; the honest lens is the balance sheet and burn. Operating cash flow was -$25.9M against just $21.8M of cash (itself down 21.5%), i.e. well under one year of runway, while long-term debt rose 31% to $30.7M and $5.45M of debt is current. To survive, Dario almost certainly must raise capital — meaning more dilution on top of the reverse split, or more debt onto an already levered, cash-poor balance sheet. That financing outcome is binary and unknowable, which is the definition of 'avoid.'